Q2 2026 delivered 6% revenue growth and a 56% increase in non-GAAP EPS, driven by strong U.S. and international spine and trauma performance. Adjusted gross margin expanded to 69.4%, and full-year EPS guidance was raised, with continued focus on product innovation and integration of recent acquisit…
Q2 2026 delivered 6% revenue growth (9% excluding Nevro), record non-GAAP EPS, and 200 bps gross margin expansion. U.S. and international spine, trauma, and neuromonitoring drove growth, while Enabling Tech and Nevro were headwinds. Full-year EPS guidance was raised, with robust capital allocation…
Globus Medical reported second-quarter 2026 results with revenue of $789.61M and diluted EPS of $1.1, while net income declined to $151.57M versus the year-ago quarter, reflecting continued top-line growth alongside margin and integration-related pressures.Financial Highlights¹ Reported as “Net sal…
Medical device company Globus Medical NYSE:GMEDwill be announcing earnings results this Thursday afternoon. Here’s what you need to know.Globus Medical beat analysts’ revenue expectations last quarter, reporting revenues of $759.9 million, up 27% year on year. It was a very strong quarter for the c…
Globus Medical GMED is scheduled to report second-quarter 2026 results on Aug. 6, after market closes.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.12 beat the Zacks Consensus Estimate by 21.74%. Globus Medical’s earnings topped estimates in each of the trailin…
